À propos de la propriété intellectuelle Formation en propriété intellectuelle Respect de la propriété intellectuelle Sensibilisation à la propriété intellectuelle La propriété intellectuelle pour… Propriété intellectuelle et… Propriété intellectuelle et… Information relative aux brevets et à la technologie Information en matière de marques Information en matière de dessins et modèles industriels Information en matière d’indications géographiques Information en matière de protection des obtentions végétales (UPOV) Lois, traités et jugements dans le domaine de la propriété intellectuelle Ressources relatives à la propriété intellectuelle Rapports sur la propriété intellectuelle Protection des brevets Protection des marques Protection des dessins et modèles industriels Protection des indications géographiques Protection des obtentions végétales (UPOV) Règlement extrajudiciaire des litiges Solutions opérationnelles à l’intention des offices de propriété intellectuelle Paiement de services de propriété intellectuelle Décisions et négociations Coopération en matière de développement Appui à l’innovation Partenariats public-privé Outils et services en matière d’intelligence artificielle L’Organisation Travailler avec nous Responsabilité Brevets Marques Dessins et modèles industriels Indications géographiques Droit d’auteur Secrets d’affaires Académie de l’OMPI Ateliers et séminaires Application des droits de propriété intellectuelle WIPO ALERT Sensibilisation Journée mondiale de la propriété intellectuelle Magazine de l’OMPI Études de cas et exemples de réussite Actualités dans le domaine de la propriété intellectuelle Prix de l’OMPI Entreprises Universités Peuples autochtones Instances judiciaires Ressources génétiques, savoirs traditionnels et expressions culturelles traditionnelles Économie Égalité des genres Santé mondiale Changement climatique Politique en matière de concurrence Objectifs de développement durable Technologies de pointe Applications mobiles Sport Tourisme PATENTSCOPE Analyse de brevets Classification internationale des brevets Programme ARDI – Recherche pour l’innovation Programme ASPI – Information spécialisée en matière de brevets Base de données mondiale sur les marques Madrid Monitor Base de données Article 6ter Express Classification de Nice Classification de Vienne Base de données mondiale sur les dessins et modèles Bulletin des dessins et modèles internationaux Base de données Hague Express Classification de Locarno Base de données Lisbon Express Base de données mondiale sur les marques relative aux indications géographiques Base de données PLUTO sur les variétés végétales Base de données GENIE Traités administrés par l’OMPI WIPO Lex – lois, traités et jugements en matière de propriété intellectuelle Normes de l’OMPI Statistiques de propriété intellectuelle WIPO Pearl (Terminologie) Publications de l’OMPI Profils nationaux Centre de connaissances de l’OMPI Série de rapports de l’OMPI consacrés aux tendances technologiques Indice mondial de l’innovation Rapport sur la propriété intellectuelle dans le monde PCT – Le système international des brevets ePCT Budapest – Le système international de dépôt des micro-organismes Madrid – Le système international des marques eMadrid Article 6ter (armoiries, drapeaux, emblèmes nationaux) La Haye – Le système international des dessins et modèles industriels eHague Lisbonne – Le système d’enregistrement international des indications géographiques eLisbon UPOV PRISMA UPOV e-PVP Administration UPOV e-PVP DUS Exchange Médiation Arbitrage Procédure d’expertise Litiges relatifs aux noms de domaine Accès centralisé aux résultats de la recherche et de l’examen (WIPO CASE) Service d’accès numérique aux documents de priorité (DAS) WIPO Pay Compte courant auprès de l’OMPI Assemblées de l’OMPI Comités permanents Calendrier des réunions WIPO Webcast Documents officiels de l’OMPI Plan d’action de l’OMPI pour le développement Assistance technique Institutions de formation en matière de propriété intellectuelle Mesures d’appui concernant la COVID-19 Stratégies nationales de propriété intellectuelle Assistance en matière d’élaboration des politiques et de formulation de la législation Pôle de coopération Centres d’appui à la technologie et à l’innovation (CATI) Transfert de technologie Programme d’aide aux inventeurs WIPO GREEN Initiative PAT-INFORMED de l’OMPI Consortium pour des livres accessibles L’OMPI pour les créateurs WIPO Translate Speech-to-Text Assistant de classification États membres Observateurs Directeur général Activités par unité administrative Bureaux extérieurs Avis de vacance d’emploi Achats Résultats et budget Rapports financiers Audit et supervision
Arabic English Spanish French Russian Chinese
Lois Traités Jugements Parcourir par ressort juridique

Union européenne

EU161

Retour

Directive 2001/18/EC of the European Parliament & of the Council of 12 March 2001 on the deliberate release into the environment of genetically modified organisms & repealing Council Directive 90/220/EEC


I

(Acts whose publication is obligatory)

DIRECTIVE 2001/18/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
of 12 March 2001
on the deliberate release into the environment of genetically modified organisms and repealing

Council Directive 90/220/EEC

THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty establishing the European Community, and in particular Article 95 thereof,

Having regard to the proposal from the Commission (1),

Having regard to the opinion of the Economic and Social Committee (2),

Acting in accordance with the procedure laid down in Article 251 of the Treaty, in the light of the joint text approved by the Conciliation Committee on 20 December 2000 (3),

Whereas:

(1)
The Report of the Commission on the Review of Council Directive 90/220/EEC of 23 April 1990 on the deliberate release into the environment of genetically modified organisms (4), adopted on 10 December 1996, identified a number of areas where improvement is needed.
(2)
There is a need for clarification of the scope of Directive 90/220/EEC and of the definitions therein.
(3)
Directive 90/220/EEC has been amended. Now that new amendments are being made to the Directive, it is desirable, for reasons of clarity and rationalisation, that the provisions in question should be recast.
(4)
Living organisms, whether released into the environment in large or small amounts for experimental purposes or as commercial products, may reproduce in the environment and cross national frontiers thereby
(1)
OJ C 139, 4.5.1998, p. 1.
(2)
OJ C 407, 28.12.1998, p. 1.
(3)
Opinion of the European Parliament of 11 February 1999 (OJ C 150, 28.5.1999, p. 363), Council Common Position of 9 December 1999 (OJ C 64, 6.3.2000, p. 1) and Decision of the European Parliament of 12 April 2000 (OJ C 40, 7.2.2001, p. 123). Decision of the European Parliament of 14 February 2001 andDecision ofthe Councilof15 February2001.
(4)
OJ L 117, 8.5.1990, p. 15. Directive as last amended by Commission Directive 97/35/EC (OJ L 169, 27.6.1997, p. 72).

affecting other Member States. The effects of such releases on the environment may be irreversible.

(5)
The protection of human health and the environment requires that due attention be given to controlling risks from the deliberate release into the environment of genetically modified organisms (CMOs).
(6)
Under the Treaty, action by the Community relating to the environment should be based on the principle that preventive action should be taken.
(7)
It is necessary to approximate the laws of the Member States concerning the deliberate release into the environment of CMOs and to ensure the safe development of industrial products utilising CMOs.
(8)
The precautionary principle has been taken into account in the drafting of this Directive and must be taken into account when implementing it.
(9)
Respect for ethical principles recognised in a Member State is particularly important. Member States may take into consideration ethical aspects when CMOs are deliberately released or placed on the market as or in products.
(10)
For a comprehensive and transparent legislative framework, it is necessary to ensure that the public is consulted by either the Commission or the Member States during the preparation of measures and that they are informed of the measures taken during the implementation of this Directive.
(11)
Placing on the market also covers import. Products containing and/or consisting of CMOs covered by this Directive cannot be imported into the Community if they do not comply with its provisions.
(12)
Making CMOs available to be imported or handled in bulk quantities, such as agricultural commodities, should be regarded as placing on the market for the purpose of this Directive.
(13)
The content of this Directive duly takes into account international experience in this field and international

trade commitments and should respect the requirements of the Cartagena Protocol on Biosafety to the Convention on Biological Diversity. As soon as possible, and in any case before July 2001, the Commission should, in the context of the ratification of the Protocol, submit the appropriate proposals for its implementation.

(14)
Cuidance on the implementation of provisions related to the definition of the placing on the market in this Directive should be provided by the Regulatory Committee.
(15)
When defining 'genetically modified organism' for the purpose of this Directive, human beings should not be considered as organisms.
(16)
The provisions of this Directive should be without prejudice to national legislation in the field of environmental liability, while Community legislation in this field needs to be complemented by rules covering liability for different types of environmental damage in all areas of the European Union. To this end the Commission has undertaken to bring forward a legislative proposal on environmental liability before the end of 2001, which will also cover damage from CMOs.
(17)
This Directive should not apply to organisms obtained through certain techniques of genetic modification which have conventionally been used in a number of applications and have a long safety record.
(18)
It is necessary to establish harmonised procedures and criteria for the case-by-case evaluation of the potential risks arising from the deliberate release of CMOs into the environment.
(19)
A case-by-case environmental risk assessment should always be carried out prior to a release. It should also take due account of potential cumulative long-term effects associated with the interaction with other CMOs and the environment.
(20)
It is necessary to establish a common methodology to carry out the environmental risk assessment based on independent scientific advice. It is also necessary to establish common objectives for the monitoring of CMOs after their deliberate release or placing on the market as or in products. Monitoring of potential cumulative long-term effects should be considered as a compulsory part of the monitoring plan.
(21)
Member States and the Commission should ensure that systematic and independent research on the potential risks involved in the deliberate release or the placing on the market of CMOs is conducted. The necessary resources should be secured for such research by Member States and the Community in accordance with their budgetary procedures and independent researchers should be given access to all relevant material, while respecting intellectual property rights.
(22)
The issue of antibiotic-resistance genes should be taken into particular consideration when conducting the risk assessment of CMOs containing such genes.
(23)
The deliberate release of CMOs at the research stage is in most cases a necessary step in the development of new products derived from, or containing CMOs.
(24)
The introduction of CMOs into the environment should be carried out according to the 'step by step' principle. This means that the containment of CMOs is reduced and the scale of release increased gradually, step by step, but only if evaluation of the earlier steps in terms of protection of human health and the environment indicates that the next step can be taken.
(25)
No CMOs, as or in products, intended for deliberate release are to be considered for placing on the market without first having been subjected to satisfactory field testing at the research and development stage in ecosystems which could be affected by their use.
(26)
The implementation of this Directive should be carried out in close liaison with the implementation of other relevant instruments such as Council Directive 91/414/EEC of 15 July 1991 concerning the placing of plant protection products on the market (1). In this context the competent authorities concerned with the implementation of this Directive and of those instruments, within the Commission and at national level, should coordinate their action as far as possible.
(27)
Concerning the environmental risk assessment for part C, risk management, labelling, monitoring, information to the public and safeguard clause, this Directive should be a point of reference for CMOs as or in products authorised by other Community legislation which should therefore provide for a specific environmental risk assessment, to be carried out in accordance with the principles set out in Annex II and on the basis of information specified in Annex III without prejudice to additional requirements laid down by the Community legislation mentioned above, and for requirements as regards risk management, labelling, monitoring as appropriate, information to the public and safeguard clause at least equivalent to that laid down in this Directive. To this end it is necessary to provide for cooperation with the Community and Member State bodies mentioned in this Directive for the purpose of its implementation.
(1)
OJ L 230, 19.8.1991, p. 1. Directive as last amended by Commission Directive 1999/80/EC (OJ L 210, 10.8.1999, p. 13).
(28)
It is necessary to establish a Community authorisation procedure for the placing on the market of CMOs, as or in products, where the intended use of the product involves the deliberate release of the organism(s) into the environment.
(29)
The Commission is invited to conduct a study which should contain an assessment of various options to improve further the consistency and efficiency of this framework, particularly focusing on a centralised authorisation procedure for the placing on the market of CMOs within the Community.
(30)
For sectoral legislation, monitoring requirements may have to be adapted to the product concerned.
(31)
Part C of this Directive does not apply to products covered by Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products (1), provided that it includes an environmental risk assessment equivalent to that provided for by this Directive.
(32)
Any person, before undertaking a deliberate release into the environment of a CMO, or the placing on the market of CMOs, as or in products, where the intended use of the product involves its deliberate release into the environment, is to submit a notification to the national competent authority.
(33)
That notification should contain a technical dossier of information including a full environmental risk assessment, appropriate safety and emergency response, and, in the case of products, precise instructions and conditions for use, and proposed labelling and packaging.
(34)
After notification, no deliberate release of CMOs should be carried out unless the consent of the competent authority has been obtained.
(35)
A notifier should be able to withdraw his dossier at any stage of the administrative procedures laid down in this Directive. The administrative procedure should come to an end when a dossier is withdrawn.
(36)
Rejection of a notification for the placing on the market of a CMO as or in products by a competent authority should be without prejudice to the submission of a notification of the same CMO to another competent authority.
(37)
An agreement should be reached at the end of the mediation period when no objections remain.
(38)
Rejection of a notification following a confirmed negative assessment report should be without prejudice to future decisions based on the notification of the same CMO to another competent authority.
(39)
In the interests of the smooth functioning of this Directive, Member States should be able to avail themselves of the various provisions for the exchange of information and experience before having recourse to the safeguard clause in this Directive.
(40)
In order to ensure that the presence of CMOs in products containing, or consisting of, genetically modified organisms is appropriately identified, the words 'This product contains genetically modified organisms' should appear clearly either on a label or in an accompanying document.
(41)
A system should be designed using the appropriate committee procedure, for the assignment of a unique identifier to CMOs, taking into account relevant developments in international fora.
(42)
It is necessary to ensure traceability at all stages of the placing on the market of CMOs as or in products authorised under part C of this Directive.
(43)
It is necessary to introduce into this Directive an obligation to implement a monitoring plan in order to trace and identify any direct or indirect, immediate, delayed or unforeseen effects on human health or the environment of CMOs as or in products after they have been placed on the market.
(44)
Member States should be able, in accordance with the Treaty, to take further measures for monitoring and inspection, for example by official services, of the CMOs as or in products placed on the market.
(45)
Means should be sought for providing possibilities for facilitating the control of CMOs or their retrieval in the event of severe risk.
(46)
Comments by the public should be taken into consideration in the drafts of measures submitted to the Regulatory Committee.
(47)
The competent authority should give its consent only after it has been satisfied that the release will be safe for human health and the environment.
(48)
The administrative procedure for granting consents for the placing on the market of CMOs as or in products should be made more efficient and more transparent and first-time consent should be granted for a fixed period.
(49)
For products for which consent has been granted for a

(1) OJ L 214, 24.8.1993, p. 1. Regulation as amended by Commission fixed period a streamlined procedure should apply as Regulation (EC) No 649/98 (OJ L 88, 24.3.1998, p. 7). regards the renewal of consent.

(50)
The existing consents granted under Directive 90/220/EEC have to be renewed in order to avoid disparities between consents granted under that Directive and those pursuant to this Directive and in order to take full account of the conditions of consent under this Directive.
(51)
Such renewal requires a transitional period during which existing consents granted under Directive 90/220/EEC remain unaffected.
(52)
When a consent is renewed, it should be possible to revise all the conditions of the original consent, including those related to monitoring and the time limitation of the consent.
(53)
Provision should be made for consultation of the relevant Scientific Committee(s) established by Commission Decision 97/579/EC (1) on matters which are likely to have an impact on human health and/or the environment.
(54)
The system of exchange of information contained in notifications, established under Directive 90/220/EEC, has been useful and should be continued.
(55)
It is important to follow closely the development and use of CMOs.
(56)
When a product containing a CMO, as or in products, is placed on the market, and where such a product has been properly authorised under this Directive, a Member State may not prohibit, restrict or impede the placing on the market of CMOs, as or in products, which comply with the requirements of this Directive. A safeguard procedure should be provided in case of risk to human health or the environment.
(57)
The Commission's European Croup on Ethics in Science and New Technologies should be consulted with a view to obtaining advice on ethical issues of a general nature regarding the deliberate release or placing on the market of CMOs. Such consultations should be without prejudice to the competence of Member States as regards ethical issues.
(58)
Member States should be able to consult any committee they have established with a view to obtaining advice on the ethical implications of biotechnology.
(59)
The measures necessary for the implementation of this Directive are to be adopted in accordance with Council Decision 1999/468/EC of 28 June 1999 laying down the procedures for the exercise of implementing powers conferred on the Commission (2).
(1)
OJ L 237, 28.8.1997, p. 18.
(2)
OJ L 184, 17.7.1999, p. 23.
(60)
The information exchange set up under this Directive should also cover experience gained with the consideration of ethical aspects.
(61)
In order to increase the effective implementation of the provisions adopted under this Directive it is appropriate to provide for penalties to be applied by Member States, including in the event of release or placing on the market contrary to the provisions of this Directive, particularly as a result of negligence.
(62)
A report to be issued every three years by the Commission, taking into account the information provided by Member States, should contain a separate chapter regarding the socioeconomic advantages and disadvantages of each category of CMOs authorised for placing on the market, which will take due account of the interest of farmers and consumers.
(63)
The regulatory framework for biotechnology should be reviewed so as to identify the feasibility of improving further the consistency and efficiency of that framework. Procedures may need to be adapted so as to optimise efficiency, and all options which might achieve that should be considered,

HAVE ADOPTED THIS DIRECTIVE:

PART A

GENERAL PROVISIONS

Article 1

Objective

In accordance with the precautionary principle, the objective of this Directive is to approximate the laws, regulations and administrative provisions of the Member States and to protect human health and the environment when:

carrying out the deliberate release into the environment of genetically modified organisms for any other purposes than placing on the market within the Community,

placing on the market genetically modified organisms as or in products within the Community.

Article 2

Definitions

For the purposes of this Directive:

(1)
'organism' means any biological entity capable of replication or of transferring genetic material;
(2)
'genetically modified organism (CMO)' means an organism, with the exception of human beings, in which the genetic material has been altered in a way that does not occur naturally by mating and/or natural recombination;

Within the terms of this definition:

(a)
genetic modification occurs at least through the use of the techniques listed in Annex I A, part 1;
(b)
the techniques listed in Annex I A, part 2, are not considered to result in genetic modification;
(3)
'deliberate release' means any intentional introduction into the environment of a CMO or a combination of CMOs for which no specific containment measures are used to limit their contact with and to provide a high level of safety for the general population and the environment;
(4)
'placing on the market' means making available to third parties, whether in return for payment or free of charge;

The following operations shall not be regarded as placing on the market:

making available genetically modified microorganisms for activities regulated under Council Directive 90/219/EEC of 23 April 1990 on the contained use of genetically modified microorganisms (1) including culture collections,

making available CMOs other than microorganisms referred to in the first indent, to be used exclusively for activities where appropriate stringent containment measures are used to limit their contact with and to provide a high level of safety for the general population and the environment, the measures should be based on the same principles of containment as laid down in Directive 90/219/EEC,

making available CMOs to be used exclusively for deliberate releases complying with the requirements laid down in part B of this Directive;

(5)
'notification' means the submission of the information required under this Directive to the competent authority of a Member State;
(6)
'notifier' means the person submitting the notification;
(7)
'product' means a preparation consisting of, or containing, a CMO or a combination of CMOs, which is placed on the market;
(8)
'environmental risk assessment' means the evaluation of risks to human health and the environment, whether direct or indirect, immediate or delayed, which the deliberate release or the placing on the market of CMOs may pose and carried out in accordance with Annex II.
(1)
OJ L 117, 8.5.1990, p. 1. Directive as amended by Directive 98/81/EC (OJ L 330 5.12.1998, p. 13).

Article 3

Exemptions

  1. This Directive shall not apply to organisms obtained through the techniques of genetic modification listed in Annex IB.
  2. This Directive shall not apply to the carriage of genetically modified organisms by rail, road, inland waterway, sea or air.

Article 4

General obligations

  1. Member States shall, in accordance with the precautionary principle, ensure that all appropriate measures are taken to avoid adverse effects on human health and the environment which might arise from the deliberate release or the placing on the market of CMOs. CMOs may only be deliberately released or placed on the market in conformity with part B or part C respectively.
  2. Any person shall, before submitting a notification under part B or part C, carry out an environmental risk assessment. The information which may be necessary to carry out the environmental risk assessment is laid down in Annex III. Member States and the Commission shall ensure that CMOs which contain genes expressing resistance to antibiotics in use for medical or veterinary treatment are taken into particular consideration when carrying out an environmental risk assessment, with a view to identifying and phasing out antibiotic resistance markers in CMOs which may have adverse effects on human health and the environment. This phasing out shall take place by the 31 December 2004 in the case of CMOs placed on the market according to part C and by 31 December 2008 in the case of CMOs authorised under part B.
  3. Member States and where appropriate the Commission shall ensure that potential adverse effects on human health and the environment, which may occur directly or indirectly through gene transfer from CMOs to other organisms, are accurately assessed on a case-by-case basis. This assessment shall be conducted in accordance with Annex II taking into account the environmental impact according to the nature of the organism introduced and the receiving environment.
  4. Member States shall designate the competent authority or authorities responsible for complying with the requirements of this Directive. The competent authority shall examine notifications under part B and part C for compliance with the requirements of this Directive and whether the assessment provided for in paragraph 2 is appropriate.
  5. Member States shall ensure that the competent authority organises inspections and other control measures as appropriate, to ensure compliance with this Directive. In the event of a release of CMO(s) or placing on the market as or in products for which no authorisation was given, the Member

State concerned shall ensure that necessary measures are taken to terminate the release or placing on the market, to initiate remedial action if necessary, and to inform its public, the Commission and other Member States.

6. Member States shall take measures to ensure traceability, in line with the requirements laid down in Annex IV, at all stages of the placing on the market of CMOs authorised under part C.

PART B

DELIBERATE RELASE OF GMOs FOR ANY OTHER PURPOSE
THAN FOR PLACING ON THE MARKET

Article 5

1. Articles 6 to 11 shall not apply to medicinal substances and compunds for human use consisting of, or containing, a CMO or combination of CMOs provided that their deliberate release for any purpose other than that of being placed on the market is authorised by Community legislation which provides:

(a)
for a specific environmental risk assessment in accordance with Annex II and on the basis of the type of information specified in Annex III without prejudice to additional requirements provided for by the said legislation;
(b)
for explicit consent prior to release;
(c)
for a monitoring plan in accordance with the relevant parts of Annex III, with a view to detecting the effects of the CMO or CMOs on human health or the environment;
(d)
in an appropriate manner for requirements relating to treatment of new items of information, information to the public, information on the results of releases, and exchanges of information at least equivalent to those contained in this Directive and in the measures taken in accordance therewith.
  1. Assessment of the risks to the environment presented by such substances and compounds shall be carried out in coordination with the national and Community authorities mentioned in this Directive.
  2. Procedures ensuring conformity of the specific environmental risk assessment and equivalence with the provisions of this Directive must be provided for by the said legislation, which must refer to this Directive.

Article 6

Standard authorisation procedure

  1. Without prejudice to Article 5, any person must, before undertaking a deliberate release of a CMO or of a combination of CMOs, submit a notification to the competent authority of the Member State within whose territory the release is to take place.
  2. The notification referred to in paragraph 1 shall include:
(a)
a technical dossier supplying the information specified in Annex III necessary for carrying out the environmental risk assessment of the deliberate release of a CMO or combination of CMOs, in particular:
(i)
general information including information on personnel and training,
(ii)
information relating to the CMO(s),
(iii) information relating to the conditions of release and the potential receiving environment,
(iv)
information on the interactions between the CMO(s) and the environment,
(v)
a plan for monitoring in accordance with the relevant parts of Annex III in order to identify effects of the CMO(s) on human health or the environment,
(vi)
information on control, remediation methods, waste treatment and emergency response plans,
(vii) a summary of the dossier;
(b)
the environmental risk assessment and the conclusions required in Annex II, section D, together with any bibliographic reference and indications of the methods used.
  1. The notifier may refer to data or results from notifications previously submitted by other notifiers, provided that the information, data and results are non confidential or these notifiers have given their agreement in writing, or may submit additional information he considers relevant.
  2. The competent authority may accept that releases of the same CMO or of a combination of CMOs on the same site or on different sites for the same purpose and within a defined period may be notified in a single notification.
  3. The competent authority shall acknowledge the date of receipt of the notification and, having considered, where appropriate, any observations by other Member States made in accordance with Article 11, shall respond in writing to the notifier within 90 days of receipt of the notification by either:
(a)
indicating that it is satisfied that the notification is in compliance with this Directive and that the release may proceed; or
(b)
indicating that the release does not fulfil the conditions of this Directive and that notification is therefore rejected.

6. For the purpose of calculating the 90 day period referred to in paragraph 5, no account shall be taken of any periods of time during which the competent authority:

(a)
is awaiting further information which it may have requested from the notifier, or
(b)
is carrying out a public inquiry or consultation in accordance with Article 9; this public inquiry or consultation shall not prolong the 90 day period referred to in paragraph 5 by more than 30 days.
  1. If the competent authority requests new information it must simultaneously give its reasons for so doing.
  2. The notifier may proceed with the release only when he has received the written consent of the competent authority, and in conformity with any conditions required in this consent.
  3. Member States shall ensure that no material derived from CMOs which are deliberately released in accordance with part B is placed on the market, unless in accordance with part C.

Article 7

Differentiated procedures

  1. If sufficient experience has been obtained of releases of certain CMOs in certain ecosystems and the CMOs concerned meet the criteria set out in Annex V, a competent authority may submit to the Commission a reasoned proposal for the application of differentiated procedures to such types of CMOs.
  2. Following its own initiative or at the latest 30 days following the receipt of a competent authority's proposal, the Commission shall,
(a)
forward the proposal to the competent authorities, which may, within 60 days, present observations and at the same time;
(b)
make available the proposal to the public which may, within 60 days, make comments; and
(c)
consult the relevant Scientific Committee(s) which may, within 60 days give an opinion.

3. A decision shall be taken on each proposal in accordance with the procedure laid down in Article 30(2). This decision shall establish the minimum amount of technical information from Annex III necessary for evaluating any foreseeable risks from the release, in particular:

(a)
information relating to the CMO(s);
(b)
information relating to the conditions of release and the potential receiving environment;
(c)
information on the interactions between the CMO(s) and the environment;
(d)
the environmental risk assessment.
  1. This decision shall be taken within 90 days of the date of the Commission's proposal or of receipt of the competent authority's proposal. This 90 day period shall not take into account the period of time during which the Commission is awaiting the observations of competent authorities, the comments of the public or the opinion of Scientific Committees, as provided for in paragraph 2.
    1. The decision taken under paragraphs 3 and 4 shall provide that the notifier may proceed with the release only when he has received the written consent of the competent authority. The notifier shall proceed with the release in conformity with any conditions required in this consent.
    2. The decision taken under paragraphs 3 and 4 may provide that releases of a CMO or of a combination of CMOs on the same site or on different sites for the same purpose and within a defined period may be notified in a single notification.
  2. Without prejudice to paragraphs 1 to 5, Commission Decision 94/730/EC of 4 November 1994 establishing simplified procedures concerning the deliberate release into the environment of genetically modified plants pursuant to Article 6(5) of Council Directive 90/220/EEC (1) shall continue to apply.
  3. Where a Member State decides to make use or not of a procedure established in a decision taken in accordance with paragraphs 3 and 4 for releases of CMOs within its territory, it shall inform the Commission thereof.

Article 8

Handling of modifications and new information

1. In the event of any modification of, or unintended change to, the deliberate release of a CMO or of a combination of CMOs which could have consequences with regard to risks for human health and the environment after the competent authority has given its written consent, or if new information has become available on such risks, either while the notification is being examined by the competent authority of a Member State or after that authority has given its written consent, the notifier shall immediately:

(1) OJ L 292, 12.11.1994, p. 31.

(a)
take the measures necessary to protect human health and the environment;
(b)
inform the competent authority in advance of any modification or as soon as the unintended change is known or the new information is available;
(c)
revise the measures specified in the notification.

2. If information becomes available to the competent authority referred to in paragraph 1 which could have significant consequences with regard to risks for human health and the environment or under the circumstances described in paragraph 1, the competent authority shall evaluate such information and make it available to the public. It may require the notifier to modify the conditions of, suspend or terminate the deliberate release and shall inform the public thereof.

Article 9

Consultation of and information to the public

  1. Member States shall, without prejudice to the provisions of Articles 7 and 25, consult the public and, where appropriate, groups on the proposed deliberate release. In doing so, Member States shall lay down arrangements for this consultation, including a reasonable time-period, in order to give the public or groups the opportunity to express an opinion.
  2. Without prejudice to the provisions of Article 25:

Member States shall make available to the public information on all part B releases of CMOs in their territory;

the Commission shall make available to the public the information contained in the system of exchange of information pursuant to Article 11.

Article 10

Reporting by notifiers on releases

After completion of a release, and thereafter, at any intervals laid down in the consent on the basis of the results of the environmental risk assessment, the notifier shall send to the competent authority the result of the release in respect of any risk to human health or the environment, with, where appropriate, particular reference to any kind of product that the notifier intends to notify at a later stage. The format for the presentation of this result shall be established in accordance with the procedure laid down in Article 30(2).

Article 11

Exchange of information between competent authorities and the Commission

1. The Commission shall set up a system of exchange of the information contained in the notifications. The competent

authorities shall send to the Commission, within 30 days of its receipt, a summary of each notification received under Article

6. The format of this summary shall be established and modified if appropriate in accordance with the procedure laid down in Article 30(2).

  1. The Commission shall, at the latest 30 days following their receipt, forward these summaries to the other Member States, which may, within 30 days, present observations through the Commission or directly. At its request, a Member State shall be permitted to receive a copy of the full notification from the competent authority of the relevant Member State.
  2. The competent authorities shall inform the Commission of the final decisions taken in compliance with Article 6(5), including where relevant the reasons for rejecting a notification, and of the results of the releases received in accordance with Article 10.
  3. For the releases of CMOs referred to in Article 7, once a year Member States shall send a list of CMOs which have been released on their territory and a list of notifications that were rejected to the Commission, which shall forward them to the competent authorities of the other Member States.

PART C

PLACING ON THE MARKET OF GMOs AS OR IN PRODUCTS

Article 12

Sectoral legislation

  1. Articles 13 to 24 shall not apply to any CMO as or in products as far as they are authorised by Community legislation which provides for a specific environmental risk assessment carried out in accordance with the principles set out in Annex II and on the basis of information specified in Annex III without prejudice to additional requirements provided for by the Community legislation mentioned above, and for requirements as regards risk management, labelling, monitoring as appropriate, information to the public and safeguard clause at least equivalent to that laid down in this Directive.
  2. As far as Council Regulation (EEC) No 2309/93 is concerned, Articles 13 to 24 of this Directive shall not apply to any CMO as or in products as far as they are authorised by that Regulation provided that a specific environmental risk assessment is carried out in accordance with the principles set out in Annex II to this Directive and on the basis of the type of information specified in Annex III to this Directive without prejudice to other relevant requirements as regards risk assessment, risk management, labelling, monitoring as appropriate, information to the public and safeguard clause provided by Community legislation concerning medicinal products for human and veterinary use.
  3. Procedures ensuring that the risk assessment, requirements regarding risk management, labelling, monitoring as appropriate, information to the public and safeguard clause are equivalent to those laid down in this Directive shall be

introduced, in a Regulation of the European Parliament and of the Council. Future sectoral legislation based on the provisions of that Regulation shall make a reference to this Directive. Until the Regulation enters into force, any CMO as or in products as far as they are authorised by other Community legislation shall only be placed on the market after having been accepted for placing on the market in accordance with this Directive.

4. During evaluation of the requests for the placing on the market of the CMOs referred to in paragraph 1, the bodies established by the Community under this Directive and by Member States for the purpose of implementing this Directive shall be consulted.

Article 13

Notification procedure

1. Before a CMO or a combination of CMOs as or in products is placed on the market, a notification shall be submitted to the competent authority of the Member State where such a CMO is to be placed on the market for the first time. The competent authority shall acknowledge the date of receipt of the notification and immediately forward the summary of the dossier referred to in paragraph 2(h) to the competent authorities of the other Member States and the Commission.

The competent authority shall without delay examine whether the notification is in accordance with paragraph 2 and shall, if necessary, ask the notifier for additional information.

When the notification is in accordance with paragraph 2, and at the latest when it sends its assessment report in accordance with Article 14(2), the competent authority shall forward a copy of the notification to the Commission which shall, within 30 days of its receipt, forward it to the competent authorities of the other Member States.

2. The notification shall contain:

(a)
the information required in Annexes III and IV. This information shall take into account the diversity of sites of use of the CMO as or in a product and shall include information on data and results obtained from research and developmental releases concerning the impact of the release on human health and the environment;
(b)
the environmental risk assessment and the conclusions required in Annex II, section D;
(c)
the conditions for the placing on the market of the product, including specific conditions of use and handling;
(d)
with reference to Article 15(4), a proposed period for the consent which should not exceed ten years;
(e)
a plan for monitoring in accordance with Annex VII, including a proposal for the time-period of the monitoring plan; this time-period may be different from the proposed period for the consent;
(f)
a proposal for labelling which shall comply with the requirements laid down in Annex IV. The labelling shall clearly state that a CMO is present. The words 'this product contains genetically modified organisms' shall appear either on a label or in an accompanying document;
(g)
a proposal for packaging which shall comprise the requirements laid down in Annex IV;
(h)
a summary of the dossier. The format of the summary shall be established in accordance with the procedure laid down in Article 30(2).

If on the basis of the results of any release notified under part B, or on other substantive, reasoned scientific grounds, a notifier considers that the placing on the market and use of a CMO as or in a product do not pose a risk to human health and the environment, he may propose to the competent authority not to provide part or all of the information required in Annex IV, section B.

  1. The notifier shall include in this notification information on data or results from releases of the same CMOs or the same combination of CMOs previously or currently notified and/or carried out by the notifier either inside or outside the Community.
  2. The notifier may also refer to data or results from notifications previously submitted by other notifiers or submit additional information he considers relevant, provided that the information, data and results are non-confidential or these notifiers have given their agreement in writing.
  3. In order for a CMO or combination of CMOs to be used for a purpose different from that already specified in a notification, a separate notification shall be submitted.
  4. If new information has become available with regard to the risks of the CMO to human health or the environment, before the written consent is granted, the notifier shall immediately take the measures necessary to protect human health and the environment, and inform the competent authority thereof. In addition, the notifier shall revise the information and conditions specified in the notification.

Article 14

Assessment report

1. On receipt and after acknowledgement of the notification in accordance with Article 13(2), the competent authority shall examine it for compliance with this Directive.

2. Within 90 days after receipt of the notification the competent authority shall:

prepare an assessment report and send it to the notifier. A subsequent withdrawal by the notifier shall be without prejudice to any further submission of the notification to another competent authority;

in the case referred to in paragraph 3(a), send its report, together with the information referred to in paragraph 4 and any other information on which it has based its report, to the Commission which shall, within 30 days of its receipt, forward it to the competent authorities of the other Member States.

In the case referred to paragraph 3(b), the competent authority shall send its report, together with the information referred to in paragraph 4 and any other information on which it has based its report, to the Commission no earlier than 15 days after sending the assessment report to the notifier and no later than 105 days after receipt of the notification. The Commission shall, within 30 days of its receipt, forward the report to the competent authorities of the other Member States.

3. The assessment report shall